Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Varicella vaccine - live
GlaxoSmithKline Australia Pty Ltd
Medicine Registered
1 VARILRIX ® _Varicella vaccine _ _ _ CONSUMER MEDICINE INFORMATION LEAFLET WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions about VARILRIX vaccine. It does not contain all the available information. It does not take the place of talking to your doctor, nurse or pharmacist. All medicines and vaccines have risks and benefits. Your doctor has weighed the possible risks of you or your child having VARILRIX against the expected benefits. IF YOU HAVE ANY CONCERNS ABOUT VARILRIX TALK TO YOUR DOCTOR, NURSE OR PHARMACIST. KEEP THIS LEAFLET WITH THIS VACCINE. You may need to read it again WHAT VARILRIX IS USED FOR VARILRIX is a vaccine used in children aged 9 months or older, adolescents and adults to prevent chickenpox. Groups who would benefit mostly from vaccination include: adults not immunised (protected) against chickenpox, especially those in ‘at-risk’ occupations such as health care workers, teachers and workers in child care centres adults not immunised, who are parents of young children adults and children not immunised, who live in the same house with people who have lowered immunity and have no history of chickenpox. The vaccine works by causing the body to produce its own protection (antibodies) against this disease. Chickenpox is caused by a virus called the varicella-zoster virus. VARILRIX vaccine contains a weakened form of the chickenpox (varicella-zoster) virus. Chickenpox is a highly infectious disease, which usually causes an itchy, red rash with blisters. After about 1 week, most of the blisters have normally crusted over. The rash can appear on the face, scalp, body, or in the mouth, eyes and bottom. Other Read the complete document
1 VARILRIX® PRODUCT INFORMATION VARICELLA VACCINE, LIVE ATTENUATED NAME OF THE DRUG VARILRIX is a live virus vaccine for immunisation against varicella. DESCRIPTION VARILRIX is a lyophilised preparation of the live attenuated Oka strain of varicella-zoster virus, obtained by propagation of the virus in MRC5 human diploid cell culture. Each 0.5ml dose of the reconstituted vaccine contains not less than 10 3.3 plaque-forming units (PFU) of the varicella-zoster virus. The vaccine also contains amino acids, human albumin, lactose, neomycin sulphate, and polyalcohols. VARILRIX does not contain a preservative. The manufacture of this product includes exposure to bovine derived materials. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product. VARILRIX meets the World Health Organisation requirements for biological substances and for varicella vaccines. PHARMACOLOGY VARILRIX produces an attenuated clinically inapparent varicella infection in susceptible subjects, with the subsequent production of varicella-specific antibodies CLINICAL TRIALS EFFICACY STUDIES The efficacy of GlaxoSmithKline (GSK)’s Oka/RIT varicella vaccines in preventing confirmed varicella disease (varicella cases were confirmed by, polymerase chain reaction {PCR} or exposure to a varicella case) has been evaluated in a large active controlled clinical trial in which children aged 12-22 months received one dose of VARILRIX (N = 2263) or two doses of _PRIORIX-TETRA _(N = 2279). The co-primary objective of this trial with respect to Varilrix was to demonstrate vaccine efficacy of ≥60% in comparison to Priorix. The efficacy of Varilrix (one dose) v Read the complete document